Leqvio FDA Approval

A2 Access - majority of Leqvio® patients will be covered by medical benefit, reducing access hurdles Payer Mix Administration Acquisition Access restrictions (step edits, prior authorizations) Reimbursement of administrative effort Part B FFS (39%) Leqvio® Medicare Advantage (19%) Commercial (34%) PCSK9i mAbs HCP-administered Self-administered Buy-and-bill Buy-and-bill, specialty pharmacy Buy-and-bill, specialty pharmacy Specialty or retail pharmacy Efforts reimbursed (medical benefit) CV outcomes evidence as driver of access decisions Access mirrors FDA label Focus on efficacy, safety, cost Efforts not reimbursed More favorable Less favorable CV Cardiovascular FFS-Fee For Service HCP Healthcare Professional PCSK9i - Proprotein convertase subtilisin/kexin type 9 inhibitor mAbs monoclonal Antibodies FDA Food and Drug Administration 20 LeqvioⓇ FDA Approval | December 23, 2021 | Novartis Investor Presentation U NOVARTIS | Reimagining Medicine

View entire presentation